Amendments to the Claims

1-51. (canceled)

52. (Currently amended) A stent preform for implantation in a body lumen comprising:

an elongated metallic core including a contact surface and first and second core ends;

an outer sheath disposed about the contact surface of the core, the outer sheath including a therapeutic agent and having first and second sheath ends; and

caps disposed on the ends of the outer sheath thereby encapsulating the first and second ends of the core.

53. (Previously presented) The stent preform of claim 52, wherein the therapeutic agent is selected from the group consisting of cyclosporine A, imatinib mesylate, curcumin, and rapamycin.

54. (Previously presented) The stent preform of claim 52, wherein the therapeutic agent is disposed within pores of the outer sheath.

55. (Previously presented) The stent preform of claim 52, wherein the core is formed of shape-memory alloy.

56. (Previously presented) The stent preform of claim 52, wherein the outer sheath is formed of a polymeric material.

57. (Previously presented) The stent preform of claim 56, wherein the polymeric material is biostable.

58. (Previously presented) The stent preform of claim 52, further comprising a release

mechanism disposed over the outer sheath.

59. (Previously presented) The stent preform of claim 58, wherein the release mechanism is a bioabsorbable polymer.

60. (Previously presented) The stent preform of claim 52, wherein the therapeutic agent is coated on the outer sheath.

61. (Previously presented) The stent preform of claim 60, wherein a release mechanism is disposed over the therapeutic agent.

62. (Previously presented) The stent preform of claim 52, wherein the outer sheath includes two therapeutic agents.

63. (Previously presented) The stent preform of claim 62, wherein the two therapeutic agents are cyclosporine A and rapamycin, imatinib mesylate and rapamycin, or curcumin and rapamycin.

64. (Previously presented) A method of treating a vascular disease of a patient with the stent preform of claim 52, the method comprising:

determining a prevalent disease process in the pathology of the vascular disease;

selecting the therapeutic agent to treat or prevent the prevalent disease process, the stent preform including the therapeutic agent; and

implanting the stent preform in the patient to treat the vascular disease.

65. (Previously presented) The method of claim 64, wherein implanting the stent preform includes implanting a plurality of stent preforms.

66. (Previously presented) The method of claim 65, wherein the plurality of stent preforms are interlaced to form a stent.

67. (Previously presented) The method of claim 64, wherein the therapeutic agent is selected from the group consisting of cyclosporine A, imatinib mesylate, curcumin, and rapamycin.

68. (Previously presented) The method of claim 64, wherein selecting the therapeutic agent includes selecting two therapeutic agents.

69. (Previously presented) The stent preform of claim 68, wherein the two therapeutic agents are cyclosporine A and rapamycin, imatinib mesylate and rapamycin, or curcumin and rapamycin.